|
AGPAT3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.98919786093188E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.71509997502073E-09 |
| Normal-vs-Stage2 |
1.984310E-03 |
| Normal-vs-Stage3 |
8.37430014222207E-10 |
| Normal-vs-Stage4 |
7.15330017442284E-10 |
| Stage1-vs-Stage2 |
3.015600E-01 |
| Stage1-vs-Stage3 |
3.302200E-02 |
| Stage1-vs-Stage4 |
1.908200E-02 |
| Stage2-vs-Stage3 |
4.901700E-02 |
| Stage2-vs-Stage4 |
2.974100E-02 |
| Stage3-vs-Stage4 |
6.570800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.98399979673059E-10 |
| Normal-vs-AfricanAmerican |
2.161700E-03 |
| Normal-vs-Asian |
5.12159999965789E-07 |
| Caucasian-vs-AfricanAmerican |
3.525600E-01 |
| Caucasian-vs-Asian |
5.390800E-01 |
| AfricanAmerican-vs-Asian |
4.686000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.67749999999689E-05 |
| Normal-vs-Female |
7.25420001845833E-09 |
| Male-vs-Female |
2.540000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.6701999994726E-07 |
| Normal-vs-Age(41-60Yrs) |
1.34949829089237E-11 |
| Normal-vs-Age(61-80Yrs) |
1.12030000054553E-07 |
| Normal-vs-Age(81-100Yrs) |
9.936300E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.938020E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.404000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.456600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.323600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.424600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.202200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.664260E-02 |
| Classical-VS-Follicular |
8.540000E-01 |
| Classical-VS-Other |
8.945200E-01 |
| Classical-VS-Normal |
5.24279952784923E-10 |
| Tall-VS-Follicular |
4.698400E-02 |
| Tall-VS-Other |
7.118200E-01 |
| Tall-VS-Normal |
1.60019997252903E-09 |
| Follicular-VS-Other |
8.162800E-01 |
| Follicular-VS-Normal |
3.03670000001421E-06 |
| Other-VS-Normal |
2.800200E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.77859999453511E-08 |
| Normal-vs-N1 |
1.79709580550025E-11 |
| N0-vs-N1 |
1.004670E-03 |
|
|
